Japan Nods Include Global Firsts For Duvroq, Vafseo And First Local Biosimilar Humira

Plus Five-Product Bonanza For Novartis

 
• By Ian Haydock
  
Generate a summary of this article
Listen to this article
Beta

Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.

Hand rubbers stamps approval on documentation
Multiple Major New Approvals In Japan • Source: Shutterstock

Japan’s ministry of health, labor and welfare (MHLW) has issued formal final approvals to a sizable group of new drugs which includes a number of significant products - the country’s first biosimilar version of Humira, second novel HIF-PH inhibitor for renal anemia and a cluster of five products from Novartis, which the Swiss group described as an “unprecedented milestone.”

Novartis AG has now received seven new product marketing authorizations already in Japan this year, notably including spinal muscular...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Japan

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By Lisa Takagi

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By Sue Sutter

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

Progress Or Hype? Looking At A Decade Of Cell Therapy In Japan

 
• By Lisa Takagi

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting reimbursement prices. How has the sector panned out over the last decade?

Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices

 
• By Lisa Takagi

A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.

More from Asia

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By Lisa Takagi

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By Sue Sutter

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By Vibha Sharma

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.